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Pilot study of mobile phone technology in allergic rhinitis in  
European countries. The MASK-rhinitis study  
 
Abstract 
Background 
The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis 
(MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic 
rhinitis symptoms, disease control and impact on patients’ lives. It is freely available in 20 countries 
(iOS and Android platforms).   
Aims 
To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline 
characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary 
could be identified and (iii) information gathered by this study could suggest novel research 
questions. 
Methods 
The Allergy Diary users were classified into 6 groups according to the baseline data that they entered 
into the App: (1) asymptomatic; (2) nasal symptoms excluding rhinorrhea; (3) rhinorrhea; (4) 
rhinorrhea plus 1-2 nasal/ocular symptoms; (5) rhinorrhea plus ≥3 nasal /ocular symptoms and (6) 
rhinorrhea plus all nasal/ocular symptoms. 
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Results  
By June 1, 2016, 3,260 users had registered with the Allergy Diary and 2,710 had completed the 
baseline questionnaire. Troublesome symptoms were found mainly in the users with the most 
symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work 
impairment. Sleep was impaired by troublesome symptoms and nasal obstruction. 
 
 
Conclusions 
This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple 
questionnaire administered by cell phones enables the identification of phenotypic differences 
between a priori defined rhinitis groups. The results suggest novel concepts and research questions in 
allergic rhinitis that may not be identified using classical methods. 
 
Abbreviations 
AHA: Active and Healthy Ageing 
AR: allergic rhinitis 
ARIA: Allergic Rhinitis and its Impact on Asthma 
EIP: European Innovation Partnership 
HIT: Health information technology  
ICT: information and communications technology 
MACVIA: Contre les MAladies Chroniques pour un VIellissement Actif  
MASK: MACVIA-ARIA Sentinel NetworK 
NAR: non allergic rhinitis 
AIT: specific immunotherapy 
VAS: visual analogue scale 
 
Key words: rhinitis, mobile technology, MASK-rhinitis, EIP on AHA, allergen immunotherapy 
(AIT), Allergy Diary 
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Introduction 
Survey questionnaires are important tools in clinical practice and epidemiology. The use of 
information and communications technology (ICT) or health information technology (HIT), such as 
apps running on consumer smart devices (i.e., smartphones and tablets), is becoming increasingly 
popular and has the potential to profoundly affect healthcare (1). Novel app-based collaborative 
systems can have an important role in gathering information quickly and improving coverage and 
accessibility of prevention and treatment (2). Classical tools are being replaced by newer smartphone 
technologies, providing individual measures across larger populations. However, variation in the 
mode of delivering a survey questionnaire may affect the quality of the responses collected, and data 
equivalence between survey questionnaires and apps is lacking (3). There are potential biases when 
using apps, since the information gathered is usually simple and less complete than when using 
lengthy questionnaires. Furthermore, the interpretation of studies on health effects is hindered by 
uncertainties in the exposure assessment (4). Implementing ICT innovations may also have disruptive 
consequences, so it is important to test applicability in each individual situation. In most instances, 
studies using ICT tools may have a selection bias since the phenotypic characteristics of the 
population are poorly known and the study may not be representative of the general population. Thus, 
the information provided by questionnaires and apps is almost certainly not identical, but may provide 
complementary information for understanding unmet needs of diseases. Moreover, ICT tools may 
allow the proposal of novel concepts and research questions.  
Several unmet needs have been identified in allergic rhinitis (AR). These include  optimal AR control, 
multi-morbidities, stratification of patients, promotion of multidisciplinary teams within integrated 
care pathways, endorsing innovation in clinical trials and encouraging patient empowerment (5, 6). 
Similar unmet needs have also been found in non-allergic rhinitis (NAR) (7, 8). In addition, NAR 
endotypes and phenotypes (9) need to be further evaluated to better understand pathophysiology, 
diagnosis and management (7).   
Smart devices and internet-based applications are already used in rhinitis and may help to meet some 
of the unmet needs (10-16). MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis), 
an ICT system centred around the patient (5, 17), is one of the implementation tools of the B3 Action 
Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) (18, 19). A 
mobile phone app (Allergy Diary) central to MASK-rhinitis belongs to the Région Occitanie (France). 
App users are asked to complete a short demographic questionnaire, thus providing baseline 
characteristics of their disease, and to use the touch screen to provide a daily visual analogue scale 
(VAS) score-based assessment of AR control. The Allergy Diary has been launched in 20 countries 
(5, 17).   
 
Aims 
At the onset of the project, it was proposed that a first analysis would be carried out after the 
enrolment of 3,000 users. On June 1, 2016, information on baseline characteristics was made 
available for the first 3,260 users of the MASK-rhinitis survey in Europe. The aims of this cross-
sectional pilot study were to assess whether (i) Allergy Diary users were able to provide baseline 
characteristics, (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary 
could be identified and (iii) information gathered by this pilot study might generate novel concepts 
and research questions. 
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Methods 
Users  
All consecutive users from August 1, 2015 to June 1, 2016 were included in the study. Some of the 
demographic characteristics (age, sex, country and language) were recorded. The App was used by 
those who found it via the internet, Apple store, Google Play or elsewhere. A few of the users were 
clinic patients who were asked by their physicians to use it. However, due to anonymisation of data 
that was requested in some of the countries, no specific information was gathered.  None of the users 
were enrolled in a clinical study as we aimed to have a real life assessment. There was no pan-
European promotional campaign. Several approaches were proposed in the different countries such as 
(i) an e-mail to members of the University Hospital of Montpellier during the pollen season informing 
them of MASK, (ii) an observational study in Spain, (iii) the involvement of the Allergy societies in 
Germany, Portugal and Italy and (iv) press releases and information to allergists during the EAACI 
meeting 
 
Allergy Diary 
The app collects the following data: (i) information on the AR symptoms experienced (nasal and 
ocular), (ii) disease type (intermittent/persistent), (iii) how symptoms impact users’ lives, and (iv) 
type(s) of AR treatment used (Table 1 and Annex). Geolocalized users assess their daily symptom 
control using the touchscreen functionality on their smart phone to click on 3 consecutive VAS (i.e. 
general, nasal and ocular symptoms). Mobile phone messaging facilitates the management of AR, 
providing prompts to assess disease control, to take medication, and to visit a health care provider, if 
appropriate. The system was initially deployed in 15 countries and in 15 languages (translated and 
back-translated, culturally adapted and legally compliant). It is now also available in Australia, Brazil, 
Canada, Mexico and Switzerland. 
 
Ethics 
The Terms of Use, translated into all languages and customized according to the country’s legislation, 
allow the use of the results for research purposes. The example of the UK terms of use is given in 
online supplement 1.  
The data are anonymised except for the geolocalized data which are never totally anonymous. The 
European Commission's Article 29 Working Party stated that geolocation information is personal data 
(http://ec.europa.eu/newsroom/just/item-detail.cfm?item_id=50083) and that information can only be 
collected, shared, or stored with people's express consent. This is the case for MASK since users 
agree to geolocation in the terms of use of the App. Moreover, geolocation is optional given that the 
user can allow it or not on his/her cell phone and that it can be removed at any time.  The problem of 
privacy due to geolocation was examined by the lawyers of each of the countries in which MASK has 
been launched and it was found to be in accordance with the existing laws. Moreover, geolocation is 
not used in the data mining process, nor is the phone IP. 
An IRB approval was not required. 
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Outcomes 
In this study, VAS measurements were not considered. Only the type and number of nasal/ocular 
symptoms were assessed to classify the users (Table 1 and online supplement 2).  
 
Classification of users 
The clinical differentiation between AR and NAR may be difficult. Symptoms may differ depending 
on allergen sensitivity and exposure, as well as ethnicity, cultural differences, age, sex and other 
environmental risk factors. In the ARIA report, the major symptom differentiating AR and NAR was 
proposed to be rhinorrhea (20), although this may also exist in NAR (7, 8). Rhinorrhea is thought to 
be more severe in patients with pollen allergy than in those with mite allergy. However, it appears that 
the vast majority of mite allergic patients present rhinorrhea during nasal challenge (21) (Bergman, 
personal communication) or during clinical trials (22, 23). Thus, in general, “sneezers” and “runners” 
may be ascribed to AR whereas “blockers” may be ascribed to NAR (24, 25). Patients suffering from 
AR usually present with all four of the cardinal nasal symptoms at a variable level (i.e. nasal 
obstruction, rhinorrhea, sneezing and pruritus) (26-29) and often also suffer from conjunctivitis (30, 
31).  
As a working hypothesis, we proposed to classify symptomatic participants according to rhinorrhea as 
an entry criterion (Figure 1 online).  
We then used the MeDALL results, which indicated that multi-morbidity is associated with more 
severe disease (32, 33). We hypothesized that users with many nasal and ocular symptoms have a 
more severe disease (34). Moreover, ocular symptoms are associated with severe AR (34, 35).    
Users were classified into 6 groups: (1) asymptomatic; (2) nasal symptoms excluding rhinorrhea; (3) 
rhinorrhea; (4) rhinorrhea plus 1-2 nasal/ocular symptoms; (5) rhinorrhea plus 3-5 nasal /ocular 
symptoms and (6) rhinorrhea plus all 6 nasal/ocular symptoms (Figure 1). 
The pharmacologic treatment received by the users was not considered due to the large diversity in 
this relatively small sample and also because VAS scores for a given level of AR severity are not 
impacted by medications (36). On the other hand, since there was no information on the effect of 
allergen-specific immunotherapy (AIT) on work, daily activity or sleep, we compared users who 
reported AIT with those who reported no AIT.  
 
Biases 
There are potential measurement biases when using apps since the information collected is usually 
restricted and less complete than when using lengthy paper or web-based questionnaires. Furthermore, 
the interpretation of studies on health effects is hindered by uncertainties in the exposure assessment 
of pollutants or allergens (4). However, this study was not designed to compare questionnaires with 
apps. A bias might be introduced given that the app users might be a selected subset of all patients 
which is not representative. Higher education or specific age ranges might apply. The study was not 
meant to be representative of the general population. 
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Size of the study 
In this exploratory pilot study, all registered users were included to obtain the best possible estimates 
for the specified time window.  
 
Statistical methods.  
The proportion of patients experiencing troublesome symptoms and impairment (i.e. work/school, 
daily activities and sleep) was described for each of the 6 symptom groups of the full data set. This 
aspect was further explored for subgroups suffering from particular symptoms potentially associated 
with impairment, i.e. ocular symptoms or nasal obstruction.  
The effect of AIT was also analysed. Users were classified into two groups according to AIT status: 
(i) No AIT (i.e. ‘No’ to Q6) and (ii) AIT (i.e. ‘Yes’ to Q6 and responses to Q7 and Q8). Users with a 
‘Yes’ to Q6 and no response to Q7 and/or Q8 were excluded from the AIT analysis. 
The statistical analysis used chi-square analysis. 
 
Results   
Users 
Among the 3,260 registered users, 550 did not complete the questionnaire. 2,710 files were analysable 
with reported symptoms and treatments in 20 countries (Table 1 online). Users included 1,165 women 
(43%) and 1,545 men (57%), with a mean age of 33 ± 6.6 years. Eight countries had more than 100 
users and, in some countries, numbers were low. The percentage of users who provided data ranged 
from 68.4% (UK) to 95.2% (The Netherlands). 
AIT use (Q6) was reported by 264 users. 15 of them did not respond to Q7 and/or Q8 and were 
excluded from further analyses (Figure 2 online). The number of AIT users was too low to allow 
complete analyses. However, in group 3 (rhinorrhea with no other symptom), there was a greater 
number of users with AIT than without AIT (Figure 3 online). 
 
Main results 
Users who did not report “ rhinitis” (Q1) did not report any nasal symptom (Q3) and only 5% of them 
reported ocular symptoms. The impact of the disease (troublesome symptoms, sleep, work or school, 
daily activities) in the different groups was estimated in the full data set (Table 2). Users with no 
reported nasal and ocular symptoms (Group 1) rarely had any troublesome symptoms or impairment. 
Those with symptoms but without rhinorrhea (Group 2) often had troublesome symptoms (76%) but 
few experienced impairment of work or school and daily activities. In general, the proportion of 
patients reporting troublesome symptoms and impairment increased as the number of symptoms in 
addition to rhinorrhea increased. 
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The impact of the disease on each of the 6 symptom groups in those who did not report AIT was 
similar to that in the full data set and is shown in the online supplement (Table 2 online). 
 
Asthma 
Table 3 presents results for asthma reporting. More users without rhinitis did not respond to the 
asthma question. There was no significant difference between the different groups in reported asthma. 
 
Impact of individual symptoms on impairment 
In subjects with rhinorrhea, the impact of individual symptoms on impairment is shown in Table 4. 
Impairment at work/school and of daily activities is associated with troublesome symptoms, nasal 
obstruction and ocular symptoms. On the other hand, sleep is similar and is high in all groups. 
 
Discussion 
In this pilot study, it is suggested that (i) the Allergy Diary users were able to complete the baseline 
characteristics in 20 countries using 20 languages, (ii) a simple questionnaire administered by cell 
phones on either iOS or Android platforms allows identification of phenotypic differences between a 
priori defined rhinitis groups, (iii) a simplistic approach using 6 categories can be used and (iv) 
although the sample size is relatively limited, information gathered suggested novel concepts and 
research questions on AIT or the impact of AR symptoms on work. 
 
Strengths and limitations 
The strengths of the mobile technology are obvious. However, there is a need to use appropriate 
questions, and results should be confirmed by pilot studies. The mobile technology of MASK-rhinitis 
uses epidemiological methodology stating a hypothesis, collects and analyses data to test the 
hypothesis, and reaches conclusions about the hypothesis. Moreover, it can also be applied to an 
unbiased exploratory hypothesis generating investigation purposes.   
 
Smart devices and internet-based applications are already used in rhinitis (10-15) but the hypotheses 
raised in the present study  have never been assessed. 
 
There are potential biases when using apps since there is necessarily a selection bias: those who use 
these instruments are likely to be young and well educated. Also, the information gathered is usually 
restricted and phenotypes less characterized than when using questionnaires. In the present study, we 
collected country, language, age, sex and date of entry of information. The response rate was high and 
most baseline questions were answered by users, suggesting that the Allergy Diary is simple and user 
friendly. However, we did not apply satisfaction or usability questionnaires. Moreover, we did not 
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check accuracy or the time taken to complete the self-administered survey. None of the studies 
included in a recent meta-analysis assessed how elements of user interaction design, survey 
questionnaire design and intervention design might influence mode effects (3). Our observations 
cannot offer any insights into these important questions. Larger scale studies in the future will permit 
assessments to address these elements and their interactions. 
Additional biases may be introduced by the countries with high versus low numbers of participants 
but we shall test this further to the enrolment of more users. 
 
Interpretation of the results and generalisability 
Users of the Allergy Diary were apparently able to complete the baseline characteristics. It was found 
that a few questions should be added (current and/or past asthma, current and/or past AIT). The 
question on asthma did not appear to be discriminative among the asymptomatic and symptomatic 
groups and should be re-evaluated.   
The period of study was winter and spring suggesting that the relevant allergens were indoor allergens 
(e.g. house dust mites, animal dander) and pollens. 
For the classification of rhinitis, simple phenotypic characteristics based on the information collected 
by the App could be identified. Rhinorrhea was used as the first discriminating symptom of the 
algorithm. It appears that users with rhinorrhea had increasing work or daily impairment associated 
with the increasing number of concomitant symptoms. This finding has not been previously reported 
and needs to be confirmed in other studies. However, it is in line with the MeDALL results proposing 
that multi-morbidity is associated with severity of allergic diseases (33). The impact of asthma on the 
severity of AR needs more investigations as it is likely that the questionnaire was not informative 
enough. A refined version is currently being tested. 
In the present study, nasal obstruction and ocular symptoms were associated with impaired work 
productivity. Although ocular symptoms are the most bothersome symptoms of AR (34, 35), their 
relationship with work has not been fully understood. These findings need to be confirmed using 
appropriate tests such as the Work Productivity and Activity questionnaire (WPAI-AS (37)) and 
EuroQuol (38), both of which are now embedded in the App.  
The severity of symptoms (troublesome symptoms) was associated with an impairment of work 
productivity, daily activities and sleep. However, ocular symptoms were not associated with sleep 
impairment. 
Interesting findings have been observed for AIT. A higher AIT ratio for Group 3 only suggests a 
positive impact of AIT on AR management with a reduction in occurrence of other nasal symptoms, 
although causation cannot be implied in the current study. The number of subjects is low and does not 
allow any firm conclusion. However, as for pharmacotherapy, treatment does not affect the reporting 
of impairment by symptomatic subjects. 
The mobile technology is available in 16 European countries as well as in Australia, Brazil, Canada 
and Mexico. 
This study shows how data collected via mobile technologies can provide different insights compared 
to the traditional conduct of research. Information gathered by this pilot study may suggest novel 
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concepts and research questions enabling large studies that collect real-time data on people’s location, 
environment, health and stratification (39). 
 
• The following authors participated to the translation, cultural adaptation and country dissemination 
of the App : J Bousquet, MD (1, 2), D Caimmi, MD (3, 4), A Bedbrook, BSc (1), M Bewick, 
MD (5), P Hellings, MD (6), P Devillier, MD (7), S Arnavielhe, PhD (8), C Bachert, MD (9), 
KC Bergmann, MD (10), GW Canonica, MD (11), N Chavannes, MD s (12), AA Cruz, 
MD (13), R Dahl, MD (13), P Demoly, MD (3,4), A Finkwagner (15), J Fonseca, MD (16), N 
Guldemond, MD (17), T Haahtela, MD (18), B Hellqvist-Dahl, PhD (19), J Just, MD (20), T 
Keil, MD (21), L Klimek, MD (22), ML Kowalski, MD (23), M Kuitunen, MD (24), P Kuna, 
MD (25), V Kvedariene, MD (26), D Laune, PhD (8), AM Pereira, MD (16), P Carreiro-
Martins, MD (28), E Melén, MD (29), M Morais Almeida, MD (46), J Mullol, MD (30), A 
Muraro, MD (31), R Murray, PhD (32), L Nogueira-Silva, MD (33), N Papadopoulos, 
MD (34), G Passalacqua, MD (11), F Portejoie (1), D Price, MD (35), D Ryan, MD (36), B 
Samolinski, MD (37), A Sheikh, MD (38), V Siroux, PhD (39), O Spranger (15), A Todo 
Bom, MD (40), PV Tomazic, MD (41), A Valero, MD (45), E Valovirta, MD (27), A 
Valiulis, MD (44), O VandenPlas, MD (43), M Wickman, MD (29), T Zuberbier, MD (10) 
 
• G De Vries, PhD (14), and M van Eerd (14) developed the App 
• E Mathieu-Dupas, PhD (8) analysed the results 
• S van der Meulen (42) was the lawyer 
 
Upon submission of a manuscript all co-authors should also be registered with correct e-mail 
addresses. 
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Table 1: Questions on symptoms and impact of symptoms 
Q1: I have rhinitis: Yes/No 
Q2: I have asthma: Yes/No 
Q3: My symptoms (tick) 
 Runny nose 
 Itchy nose 
 Sneezing 
 Congestion (blocked nose) 
 Red eyes 
 Itchy eyes 
 Watery eyes 
Q4: How they affect me: My symptoms (tick) 
 Affect my sleep 
 Restrict my daily activities 
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 Restrict my participation in school or work 
 Are troublesome 
Q5: Medications 
Q6: Are you currently receiving immunotherapy (a small dose of the thing you are allergic to, usually taken as 
an injection or placed under your tongue)? Yes/No 
If YES to Q6 (Q7 and Q8) 
Q7: What allergy is this? 
 Grass pollen 
 Parietaria pollen 
 Birch pollen 
 Other pollen 
 Dust mite 
 Animal 
 Cypress tree pollen 
 Don’t know 
 Add allergy 
Q8: How do you receive your treatment? 
 Injection 
 Tablet under the tongue 
 Drops under the tongue 
 Spray under the tongue 
 Other 
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Table 2: Impairment in users of the full data set (N=2,710) 
Group Symptom N Troublesome 
symptoms 
Impairment 
 
Rhinorrhea 
Any other 
symptom 
  
Work or 
school 
Daily 
activities 
Sleep Any 
1 NO NO 283 20 (7%) 5 (2%) 11 (4%) 11 (4%) 18 (6%) 
1* NO Yes 39 23 (59%) 6 (15%) 5 (13%) 8 (21%) 15 (38%) 
2 NO Yes 614 467 (76%) 118 (19%) 170 (28%) 210 (34%) 319 (52%) 
3 YES None 87 23 (26%) 8 (9%) 17 (20%) 36 (41%) 55 (63%) 
4 YES 1 or 2 366 258 (70%) * 68 (19%)* 100 (27%) 95 (26%) 188 (51%) 
5 YES 3, 4 or 5 870 728 (84%) ** 256 (29%)** 394 (45%)* 342 (39%)** 585 (67%) 
6 YES ALL (6) 451 398 (88%) 
220 
(49%)*** 
284 
(63%)*** 
233 
(52%)*** 
365 (81%) 
Chi2 test : P<0.01 group 4 vs 3*; group 5 vs 4
**
; group 6 vs 5
***
 
*: subjects who answered “no rhinitis” Q1 
 
Table 3: Reporting of asthma 
 
Population with informed symptoms  (n=2710) 
Group N Asthma (Yes) No Asthma NA 
1 322 107 (33.2%) 135 (41.9%) 74 (22.9%) 
2 614 202 (32.9%) 339 (55.2%) 60 (10%) 
3 87 62 (71.3%) 17 (19.5%) 7 (8.0%) 
4 366 105 (28.7%) 208 56.8%) 47 (12.8%) 
5 870 259 (29.8%) 521 60.0%) 72 (8.3%) 
6 451 157 34.8%) 244 (54.1%) 42 (9.3%) 
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Table 4: Impact of individual symptoms on impairment in subjects with rhinorrhea 
 
Subjects with rhinorrhea (N=1774) 
Impairment 
Work or 
school 
Daily 
activities 
Sleep 
Troublesome 
symptoms 
Yes N=1407 483 (34%) ** 659 (47%) ** 603 (43%) ** 
No N=367 69 (19%) 136 (37%) 103 (28%) 
Nasal 
obstruction 
Yes N=1274 467 (37%) *** 635 (50%) *** 591 (46%) ** 
No N=500 85 (17%) 160 (32%) 115 (23%) 
Ocular 
symptoms 
Yes N=1324 461 (35%) *** 659 (50%) *** 541 (41%) NS 
No N=450 91 (20%) 136 (30%) 165 (37%) 
Chi2 test : ** P<0.01; *** P<0.001, NS: not significant 
 
Figure 1: Classification of users 
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Figure 2: Distribution of the users 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
